Kestra Medical (KMTS) Q4 2026 Earnings Call Transcript

Kestra Medical Technologies reported Q4 revenue of $28.6M (+66% YoY) and gross margin of 54.8% (+10.5ppt YoY), with GAAP net loss of $38.8M (improved from $51.1M) and operating cash burn reduced to $18.7M (from $24.1M). For FY2027, the company guided revenue to $137M (+44% YoY), supported by rapid growth in prescriptions (+63% YoY in Q4) and expansion to 130 active sales territories. Management also cited a 24% cost-of-capital reduction from a new $200M term loan facility with Pharmakon (only $75M funded at close) and ongoing product/commercial upgrades (enhanced ASSURE detection algorithm shipped to all patients).

Analysis

KMTS is winning on the mechanics that matter: higher utilization, better payer mix, and a rental model that scales gross profit faster than scripts. The immediate beneficiary is KMTS equity, but the second-order loser is the incumbent WCD vendor because this is a fleet business: once an account workflow tilts toward one platform, replacement takes years, not quarters. That makes the share shift more durable than a one-quarter prescription beat would imply, and it also raises the value of clinical evidence versus pure hardware feature parity.

The near-term risk is that investors extrapolate the top line faster than the salesforce can absorb it. Management is still in a ramp phase, so 1-3 month numbers are vulnerable to lumpy territory productivity, while 6-18 month upside depends on new reps reaching full run-rate, payer conversion staying high, and the new manuscript/guideline path translating into real prescribing behavior. If gross margin stalls below the mid-50s or in-network mix slips, the thesis gets hit because the model’s operating leverage is what justifies the multiple.

Contrarian view: the market may be underestimating how much of the story is distribution, not product. The real upside is not another device feature; it is widening the addressable pool by getting cardiology and heart-failure workflows to treat WCD as default bridge therapy. That is slower than bulls want, but it also means current guidance may be conservative if the recent commercial build starts compounding. Conversely, if clinical adoption does not translate into faster payer conversion, this becomes a very expensive share-gain story rather than a breakout category story.

Key Decisions for Investors

• Buy KMTS on a post-earnings pullback rather than chase strength; use a 1-3 month horizon and require sequential gross margin improvement plus stable in-network mix as confirmation.
• If options are liquid, express upside with a 3-6 month KMTS call spread instead of outright calls; the setup is constructive but still execution-sensitive during rep ramp.
• Pair long KMTS vs short IHI as a beta hedge: this isolates idiosyncratic commercial execution and evidence-driven share gains from broader med-tech multiple noise.
• Set a thesis-falsifier alert on the next quarter: if prescriptions decelerate while operating burn fails to improve, reduce exposure even if headline revenue is still growing.